Table 3.
Comparative Antioxidant Therapeutics in Rheumatic Diseases
| Disease | Promising Antioxidant(s) | Key Mechanism(s) Targeted | Evidence and Clinical Notes | References |
|---|---|---|---|---|
| RA | Curcumin (enhanced) | NF-κB inhibition, Nrf2 activation | RCT (n=45): Meriva® 1g/day = diclofenac 100mg in reducing DAS28 & CRP. Bioavailability-critical: Phospholipid formulations ↑ absorption 29-fold vs native. Synergy with DMARDs plausible. | Chandran et al103 Cuomo et al127 |
| EGCG | MMP inhibition, JAK/STAT suppression | RCT (n=60): 500mg/day ↓ DAS28, RF, anti-CCP (p<0.01). Caution: Doses >800mg/day ↑ hepatotoxicity risk (ALT elevation). Limited structural benefit. | Giordano et al128 | |
| Vitamin D | Th17/Treg balance, ↓ macrophage ROS | Meta-analysis: Supplementation ↓ DAS28 only in deficient patients (serum <20 ng/mL). Target: 40–60 ng/mL (2000–5000 IU/day). | Heidari et al129 Aranow.130 | |
| OA | Curcumin (enhanced) | COX-2/LOX inhibition, ↓ MMP-13 | Meta-analysis (8 RCTs): ↓ pain (SMD=−0.99) and ↑ function (SMD=−1.3) vs placebo. Nano-curcumin ↑ synovial bioavailability. Better GI tolerance than NSAIDs. | Dai et al131 Henrotin et al132 |
| EGCG | ↓ ADAMTS-5, ↑ aggrecan synthesis | RCT (n=107): 540mg/day ↓ cartilage degradation biomarkers (MMP-13, CTX-II) but no significant pain relief. Bioavailability limited by poor joint penetration. | Zhong et al133 | |
| Resveratrol | SIRT1 activation ↓ NF-κB, ↓ senescence |
Preclinical: Protects chondrocytes from IL-1β (in vitro). Human data lacking: Bioavailability <1% limits translation. Micelle formulations show promise. | Elmali et al134 | |
| SLE | Vitamin D | ↓ neutrophil ROS, ↑ Treg function | Meta-analysis: Every 10 ng/mL ↑ serum 25(OH)D ↓ SLEDAI by 0.94 (p<0.001). Deficiency doubles flare risk. Supplementation essential (2000–5000 IU/day). | Islam et al135 |
| NAC | Glutathione replenishment, ↓ NETosis | RCT (n=36): 2400mg/day ↓ SLEDAI by 3.6 vs 0.9 with placebo (p=0.002). ↓ renal flares by 50%. Dose-dependent nausea. | Lai et al136 | |
| EGCG | ↓ anti-dsDNA via T-cell apoptosis | Preclinical: ↓ autoantibodies and glomerulonephritis in MRL/lpr mice. No human SLE trials. Theoretical risk of hepatotoxicity at effective doses. | Wu et al137 | |
| Gout | NAC | NLRP3 inflammasome inhibition | In vitro: Blocks Monosodium Urate crystal-induced IL-1β release. No clinical RCTs. Anecdotal use in acute flares (1200–2400mg/day). | Martinon et al138 |
| Vitamin C | URAT1 inhibition mild urate-lowering | RCT (n=184): 500mg/day ↓ serum urate by 0.5 mg/dL vs placebo (p<0.01). Clinical impact minimal: No reduced flare frequency. High doses (≥2000mg) ↑ kidney stone risk. | Juraschek et al139 | |
| Scleroderma | NAC (IV/high-dose) | Glutathione ↓ vascular ROS | Open-label trial (n=40): IV NAC (5g/day) ↓ Raynaud’s attacks and ulcer healing. Fibrosis data inconclusive. Oral high-dose (1800–2400mg/day) commonly used. | Salsano et al140 |
| Antioxidant Cocktails | General ROS scavenging | Trial (n=34): Alpha-Lipoic Acid (300mg) + vitamin C/E ↓ endothelial dysfunction (p=0.03). Modest symptomatic benefit; no disease modification. | Piera-Velazquez et al141 |
Notes: The upward arrows (↑) and downward arrows (↓) are used to concisely indicate changes in levels or effects within the “Evidence & Clinical Notes” column. ↑ Indicates: An increase, enhancement, or elevation. ↓ Indicates: A decrease, reduction, lowering, or inhibition.